• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Briefing Information for the May 10, 2012 Meeting of the Antiviral Drugs Advisory Committee

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance

  

FDA

 Disclaimer

 Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

FDA Briefing Information for the May 10, 2012 Meeting of the Antiviral Drugs Advisory Committee (PDF – 544KB)

Errata to the FDA Briefing Information for the May 10, 2012 Meeting of the Antiviral Drugs Advisory Committee (PDF – 10KB)

 

 Gilead Sciences, Inc.

 Disclaimer

 The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

 Gilead Briefing Information for the May 10, 2012 Meeting of the Antiviral Drugs Advisory Committee (PDF – 6.76MB)